corporate communications 2012 oncology specialty survey november 2012
TRANSCRIPT
2Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com 2
Pra
ctic
e S
ize
Survey Overview
Primary mobile device platform
68%iPhone or
iPod touch
18%Android
5%Com-puter/ laptop
5%Tablet device
3%BlackBerry
1%Other
8%Solo
33%Hospital
16%Small
(3-5 physicians)
4%Partnership
15%
Large (More than 10 physicians)
20%
Mid-size (5-10 physicians)
• Survey included 321 Oncologists who use Epocrates
• Survey was conducted in October 2012
• Oncologists randomly selected to participate
n=321
3
>1 in 3 Oncologists use a Tablet in Practice
>
=
>
Other devices primary; tablet supplemental
Tablet only device used
Rarely uses tablet
Tablet primary; other device supplemental
Tablet & other devices used equally
45%
27%
15%
11%
2% 37%Plan to purchase iPad mini
80%Apple iPad
15%Android OS
Tablet utilization in practice2012 Tablet utilization by physicians
2% Other
3% Windows 7 OS
Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
n=105
n=122
n=321
4
Oncologists Access Epocrates Over 2 Million Times Annually with a Patient*
70%
60%Use Epocrates
Outside of the office daily
Use Epocrates During office hours
3+ times daily
Use Epocrates With a patient
daily
Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
n=321
Number of times physicians access Epocrates
Over
1 in 2
*Statement based on self-reported usage and extrapolated across the Epocrates member base
5
Nearly 40% of Oncologists Avoid 2+ ADEs Weekly with Epocrates
10%> 3
ADEs/ week
7%3 ADEs/ week
22%2 ADEs/ week
18%1 ADE/ week
43%< 3
ADEs/ month
Over
450,000ADEs are potentially
avoided annually with Epocrates*
Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
Percentage of ADEs avoided with Epocrates
n=321*Statement based on self-reported usage and extrapolated across the Epocrates member base
6
Over 400,000 Hours Likely Saved by Oncologists Annually with Epocrates*
21%> 30 minutes
25%21 – 30
minutes
20%11- 20 minutes
24%5-10 minutes
11%< 5 minutes
Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
20+ minutessaved daily
n=321*Statement based on self-reported usage and extrapolated across the Epocrates member base
oncologists report saving 20 minutes
or more daily
Nearly
1 in 2
Daily minutes saved
7
54%Frequently or
somewhat frequently learn new information
from DocAlerts
Drug Interaction Checker #1 Feature Attributed to Changing Rx Decisions
72%
Drug interactions
71%
Dosing information
46%
Adverse reactions
43%Contraindications
& cautions
15%Formulary
information
12% Other safety info
92%Make Rx changes
based on Epocrates information
Top features factoring in Rx changes*
Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
n=321
8
34% Yes, significantly
31% Yes, moderately
25% Yes, somewhat
10% No
Keeping Up with New Clinical Info a Top Challenge for Oncologists
Top 5 greatest challenges for oncologists
46% 44%
38% 36% 34%
Years in
pra
ctice
Has the level of stress grown over the years as practicing
physician?
Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
n=321
9Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
Fragmented Care Biggest Challenge Facing Patients
Top 5 greatest challenges for patients
35%
32%
14%
7%6%
93% Diagnosis
91% Tx Options
79% Prognosis
62% Viability estimates
Extre
mely
confident to
confident
Confidence in information disclosed to
patients
n=321
10
Rx information
Lifestyle change tools
Chronic Dx mgmt
Medical adherence
EHR portal
Patient education
>30% of Oncologists Have Recommended an App to Patients
66%
56%
34%
25%
23%
10%
Apps recommended to patients
Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
n=106
Top apps recommended
Calorie counter/ tracker
Weight loss tracker
Fitness app (e.g. myfitnesspal.com)
Drug information (e.g. Epocrates)
Patient educational apps
11
Physicians Struggle with App Discovery and Recommendations for Patients
App st
ore
An in
tern
et se
arch
eng
ine
A frie
nd o
r col
leag
ue
Confe
renc
e/ tr
ades
how
It's a
n ap
p I u
se
45%41% 40%
23%19%
Where physicians learn about apps to recommend
Over
50% Report not knowing
which apps are ‘good to share’
Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
n=105
n=216
12Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
“Phone Calls” Remain Primary Communication Platform for Patients and Peers
Ph
ysi
cian
to P
ati
en
t Ph
ysicia
n to
C
olle
ag
ue
Phone call
84%Phone call
43%
9%Email
32%SMS Message
2%
Patient Portal
3%
Direct Mail Video Chat
2% ~1%
Email SMS Message
Direct MailVideo Chat
7%0%
EHR System Secure Messaging
3%6%
12%
Primary methods of communication with colleagues vs. patients
n=321
13Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
Perceptions of Cancer are Increasingly Positive
How perceptions of cancer have
changed over the past 5 years:
63%
41%39%
37%
23%
n=321
Chronic Condition:A human health condition or disease that is persistent or otherwise long-lasting in its
effects*
*World Health Organization 2012
14Copyright © 2012 Epocrates, Inc. All rights reserved. To learn more about Epocrates, please visit www.epocrates.com
Oncologist Data and Information Gaps
>55% are concerned about
industry bias in journal articles & clinical trials
Most need information to help improve patient care*
38%
Comparison of
anticancer therapies
19%
Information on enrolling in clinical
trials
17%
Information on research results for existing
therapies
Oncologists highly anticipate development or technology in targeted molecular and genetic therapies
n=321